X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA FRESENIUS KABI ONCO. SHASUN PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 123.9 22.1 559.9% View Chart
P/BV x 8.5 3.1 274.1% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
FRESENIUS KABI ONCO.
Mar-13
SHASUN PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs94176 53.5%   
Low Rs4679 58.1%   
Sales per share (Unadj.) Rs214.237.7 568.3%  
Earnings per share (Unadj.) Rs5.35.1 104.8%  
Cash flow per share (Unadj.) Rs15.86.7 235.3%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.342.5 125.4%  
Shares outstanding (eoy) m56.62158.23 35.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.4 9.7%   
Avg P/E ratio x13.125.0 52.4%  
P/CF ratio (eoy) x4.418.9 23.3%  
Price / Book Value ratio x1.33.0 43.8%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,95820,135 19.7%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m2,164703 307.7%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m12,1275,963 203.4%  
Other income Rs m22918 1,274.2%   
Total revenues Rs m12,3565,981 206.6%   
Gross profit Rs m1,0091,430 70.6%  
Depreciation Rs m594258 230.2%   
Interest Rs m415-26 -1,596.5%   
Profit before tax Rs m2301,216 18.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m-73342 -21.3%   
Profit after tax Rs m302806 37.5%  
Gross profit margin %8.324.0 34.7%  
Effective tax rate %-31.728.1 -112.5%   
Net profit margin %2.513.5 18.4%  
BALANCE SHEET DATA
Current assets Rs m6,8845,102 134.9%   
Current liabilities Rs m8,4562,385 354.5%   
Net working cap to sales %-13.045.6 -28.5%  
Current ratio x0.82.1 38.1%  
Inventory Days Days62150 41.1%  
Debtors Days Days108113 94.9%  
Net fixed assets Rs m4,9705,148 96.5%   
Share capital Rs m113158 71.6%   
"Free" reserves Rs m2,8756,556 43.9%   
Net worth Rs m3,0206,732 44.9%   
Long term debt Rs m1,817952 190.9%   
Total assets Rs m13,34710,388 128.5%  
Interest coverage x1.6-45.8 -3.4%   
Debt to equity ratio x0.60.1 425.4%  
Sales to assets ratio x0.90.6 158.3%   
Return on assets %5.47.5 71.6%  
Return on equity %10.012.0 83.6%  
Return on capital %13.314.6 91.2%  
Exports to sales %46.474.5 62.2%   
Imports to sales %14.224.8 57.5%   
Exports (fob) Rs m5,6224,441 126.6%   
Imports (cif) Rs m1,7281,477 116.9%   
Fx inflow Rs m5,8435,298 110.3%   
Fx outflow Rs m2,1731,772 122.6%   
Net fx Rs m3,6693,525 104.1%   
CASH FLOW
From Operations Rs m3981,274 31.2%  
From Investments Rs m-1,635-1,204 135.8%  
From Financial Activity Rs m1,309-196 -667.3%  
Net Cashflow Rs m71-126 -56.4%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 3.6 0.3 1,200.0%  
FIIs % 17.6 9.6 183.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 9.1 435.2%  
Shareholders   20,750 42,599 48.7%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS